- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
· Topline results show TREMFYA met the primary and major secondary endpoints of axial involvement in PsA - including spinal pain and stiffness - and demonstrated significant improvement in MRI-confirmed inflammation · First-ever study to use objective MRI assessments to confirm presence of axial involvement and demonstrate axial inflammation reduction in PsA
· Topline results show TREMFYA met the primary and major secondary endpoints of axial involvement in PsA - including spinal pain and stiffness - and demonstrated significant improvement in MRI-confirmed inflammation · First-ever study to use objective MRI assessments to confirm presence of axial involvement and demonstrate axial inflammation reduction in PsA
· New results suggest earlier treatment may increase the likelihood of long-term remission · Study adds to Johnson & Johnson's overwhelming body of evidence supporting its innovative multiple myeloma therapies in second line, where earlier intervention may increase long-term remission and disease control
· New results suggest earlier treatment may increase the likelihood of long-term remission · Study adds to Johnson & Johnson's overwhelming body of evidence supporting its innovative multiple myeloma therapies in second line, where earlier intervention may increase long-term remission and disease control
CAPLYTA® significantly reduced the signs and symptoms of acute manic episodes associated with bipolar I disorder as early as Day 3, with benefits sustained through Week 3 Results build on the established efficacy, safety and tolerability profile of CAPLYTA®, further supporting its potential to reach more patients across bipolar I and II disorders
CAPLYTA® significantly reduced the signs and symptoms of acute manic episodes associated with bipolar I disorder as early as Day 3, with benefits sustained through Week 3 Results build on the established efficacy, safety and tolerability profile of CAPLYTA®, further supporting its potential to reach more patients across bipolar I and II disorders
Low rates of rash, blood clots and administration-related reactions were observed with subcutaneous treatment and prophylaxis Fewer than 1% of patients discontinued treatment due to treatment-related events at one year New findings from Johnson & Johnson build on the MARIPOSA survival benefit and strengthen evidence for RYBREVANT FASPRO plus LAZCLUZE as first-line treatment
Low rates of rash, blood clots and administration-related reactions were observed with subcutaneous treatment and prophylaxis Fewer than 1% of patients discontinued treatment due to treatment-related events at one year New findings from Johnson & Johnson build on the MARIPOSA survival benefit and strengthen evidence for RYBREVANT FASPRO plus LAZCLUZE as first-line treatment
• Reported AI adoption in oncology has increased from 19% of healthcare providers across all practice settings in 2025 to 49% of community oncologists specifically in 2026 • Meanwhile use of advanced tools like predictive models remains low, at just 19%, revealing a gap between adoption and deeper implementation
• Reported AI adoption in oncology has increased from 19% of healthcare providers across all practice settings in 2025 to 49% of community oncologists specifically in 2026 • Meanwhile use of advanced tools like predictive models remains low, at just 19%, revealing a gap between adoption and deeper implementation